Research Article
Biological and Molecular Effects of Small Molecule Kinase Inhibitors on Low-Passage Human Colorectal Cancer Cell Lines
Table 1
Clinical and pathological characteristics of patients and HROC cell lines.
| | Tumor ID | Age/Gender | Tumor location | TNM-Stage | UICC stage | Tumor type | Molecular type | Molecular alterations | | APC | TP53 | KRAS | BRAF | PIK3CA | PTEN |
| | HROC18 | 65/f | caecum | G2T2N0M0
R0L0V0 | I | Primary adenocarcinoma | spStd | mut | mut | wt | wt | mut | wt | | HROC24 | 98/m | colon ascendens | G2T2N0M0
R0L0V1 | I | Primary adenocarcinoma | spMSI-H | mut | wt | wt | mut | wt | wt | | HROC43 | 72/m | colon ascendens | G3T3N2M0
R0L1V0 | IIIb | Primary adenocarcinoma | CIMP-L | mut | mut | mut | wt | wt | wt | | HROC46* | 66/m | colon ascendens | G3T3N0M1
R2L0V1 | IV | Primary adenocarcinoma | spStd | mut | wt | mut | wt | wt | wt |
|
|
f: female, m: male, spStd: sporadic standard, spMSI: sporadic microsatellite instable, CIMP-L: CpG island methylator phenotype, and L: low, H: high. *Xenograft-derived cell line.
|
